Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland

Files in This Item:
File Description SizeFormat 
Unnderstanding Clinical Trials.pdf295.32 kBAdobe PDFDownload
Title: Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland
Authors: Kearns, CathrionaFeighery, RonanMc Caffrey, JohnHiggins, MichaelaSmith, MartinaGallagher, William M.Kelly, CiaraKelly, Catherine M.et al.
Permanent link: http://hdl.handle.net/10197/12068
Date: 16-Jul-2020
Online since: 2021-03-30T10:04:19Z
Abstract: Cancer clinical trials (CCTs) are critical to translation and development of better therapies to improve outcomes. CCTs require adequate patient involvement but accrual rates are low globally. Several known barriers impede participation and knowing how subpopulations differ in understanding of CCTs can foster targeted approaches to aid accrual and advance cancer treatments. We conducted the first nationwide survey of 1089 patients attending 14 Irish cancer centres, assessing understanding of fundamental concepts in CCT methodology and factors that influence participation, to help tailor patient support for accrual to CCTs. Two-thirds (66%) of patients reported never having been offered a CCT and only 5% of those not offered asked to participate. Misunderstanding of clinical equipoise was prevalent. There were differences in understanding of randomisation of treatment by age (p < 0.0001), ethnicity (p = 0.035) and marital status (p = 0.013), and 58% of patients and 61% previous CCT participants thought that their doctor would ensure better treatment in CCTs. Females were slightly more risk averse. Males indicated a greater willingness to participate in novel drug trials (p = 0.001, p = 0.003). The study identified disparities in several demographics; older, widowed, living in provincial small towns and fewer years-educated patients had generally poorer understanding of CCTs, highlighting requirements for targeted support in these groups.
Funding Details: European Commission Horizon 2020
Irish Research Council
Science Foundation Ireland
Funding Details: Abbvie
Inveva
Bayer
Novartis
Amgen
Type of material: Journal Article
Publisher: MDPI
Journal: Cancers
Volume: 12
Issue: 7
Keywords: CancerClincial trialsUnderstanding
DOI: 10.3390/cancers12071921
Language: en
Status of Item: Peer reviewed
ISSN: 2072-6694
This item is made available under a Creative Commons License: https://creativecommons.org/licenses/by/3.0/ie/
Appears in Collections:Conway Institute Research Collection
Biomolecular and Biomedical Science Research Collection
Medicine Research Collection

Show full item record

Page view(s)

146
checked on Apr 11, 2021

Download(s)

6
checked on Apr 11, 2021

Google ScholarTM

Check

Altmetric


If you are a publisher or author and have copyright concerns for any item, please email research.repository@ucd.ie and the item will be withdrawn immediately. The author or person responsible for depositing the article will be contacted within one business day.